drugset / Trial / NCT07629895

Myo-Inositol Alone Versus Myo-Inositol Plus Alpha-Lactalbumin in Women With Polycystic Ovary Syndrome

NCT07629895

Not yet recruiting 82 enrolled Quaid-e-Azam Medical College
RandomizedParallel-groupOpen-labelTreatment

Summary

Polycystic ovary syndrome (PCOS) is a common endocrine disorder affecting reproductive-aged women and is associated with menstrual irregularities, infertility, hyperandrogenism, obesity, and insulin resistance. Myo-inositol is commonly used as an insulin-sensitizing agent to improve reproductive and metabolic outcomes in women with PCOS. Alpha-lactalbumin may enhance the intestinal absorption and bioavailability of myo-inositol and potentially improve treatment response. This randomized controlled trial aims to compare the efficacy of myo-inositol alone versus myo-inositol plus alpha-lactalbumin in women with PCOS. Eighty-two eligible women will be randomized to receive either myo-inositol alone or myo-inositol combined with alpha-lactalbumin for 12 weeks. The study will evaluate reproductive outcomes including spontaneous conception, menstrual regularity, hirsutism, and hormonal parameters, as well as metabolic outcomes including body mass index and insulin resistance.

Timeline

Start
2026-09
Primary completion
2027-04
Completion
2027-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Alpha-Lactalbumin Protein / enzyme biologic 50 mg Oral
Subject Inositol Small molecule 2 g Oral